DL
Therapeutic Areas
Aptorum Group Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SACT-1 | Neuroblastoma and other solid tumors | Phase 1 |
| ALS-4 | Staphylococcus aureus infections (including MRSA) | Pre-clinical |
| CLS-1 | Obesity and Metabolic Disorders | Discovery |
| NAT-1 | Various Cancers | Discovery |
| Aptorum Microbiome Therapeutics | Clostridioides difficile Infection (CDI) | Pre-clinical |
Leadership Team at Aptorum Group
IH
Ian Huen
Chief Financial Officer & Executive Director
CC
Clark Cheng
Chief Scientific Officer & Executive Director
KA
Keith Anderson
Chief Operating Officer
MM
Muzammil Mansuri
Independent Non-Executive Director & Chairman of the Board
DP
David P. Luci
Independent Non-Executive Director
RS
Ronald Shigeta
Independent Non-Executive Director